To include your compound in the COVID-19 Resource Center, submit it here.


BioNTech creates cancer bispecifics from mRNA.

BioNTech AG believes its RNA therapeutics platform can produce bispecific antibodies that circumvent the manufacturing and short plasma half-life problems of other technologies, and thinks its approach can accelerate the development timeline for bispecific T cell-engaging antibodies (BiTEs) in cancer.

In June, the company published a study in Nature Medicine demonstrating RNA injection could produce functional levels of a bispecific antibody in mice with a better PK profile and less frequent dosing than its

Read the full 739 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers